免疫检查点抑制剂相关结肠炎的研究进展

doi:10.3969/j.issn.1006-5725.2024.09.023

Abstract

Abstract:

Immune checkpoint inhibitors （ICIs）， including cytotoxic T?lymphocyte?associated protein 4 （CTLA?4） inhibitors and programmed cell death receptor 1 （PD?1） inhibitors and their ligand 1 （PD?L1） inhibitors， have transformed the clinical outcomes of many patients with malignancies. programmed cell death receptor 1 （PD?1） inhibitors and their ligand 1 （PD?L1） inhibitors have changed the clinical outcomes of many patients with malignancies and have become the most important anti?tumor tools available. With the widespread use of immunotherapy， immune?related adverse events （irAEs） induced by ICIs have gradually attracted clinical attention， among which ICI?related colitis has become the most common adverse event in the gastrointestinal system. In this paper， we describe the epidemiology， pathogenesis and clinical management of ICI?related colitis， with the aim of providing reference for clinicians to identify and treat ICI?related colitis in a timely manner.

Key words: immune checkpoint inhibitors, immune?related adverse events, colitis

CLC Number:

R730.51

Xiaona MENG,Xu SUN,Huaimin LIU. Advances in the study of immune checkpoint inhibitors⁃related colitis[J]. The Journal of Practical Medicine, 2024, 40(9): 1314-1319.

Figures/Tables 1

References 46

1	ZHANG B， WU Q， ZHOU Y L， et al. Immune-related adverse events from combination immunotherapy in cancer patients： A comprehensive meta-analysis of randomized controlled trials ［J］. Inte Immunopharmacol， 2018， 63： 292-298. doi:10.1016/j.intimp.2018.08.014 doi: 10.1016/j.intimp.2018.08.014
2	PARENTE P， MAIORANO B A， CIARDIELLO D， et al. Clinic， Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity： Some News and Reappraisal from a Mono-Institutional Experience ［J］. Diagnostics （Basel， Switzerland）， 2022， 12（3）： 685-697. doi:10.3390/diagnostics12030685 doi: 10.3390/diagnostics12030685
3	LARKIN J， HODI F S， WOLCHOK J D. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma ［J］. N Engl J Med， 2015， 373（13）： 1270-1271. doi:10.1056/nejmc1509660 doi: 10.1056/nejmc1509660
4	RAMOS-CASALS M， BRAHMER J R， CALLAHAN M K， et al. Immune-related adverse events of checkpoint inhibitors ［J］. Nat Rev Dis Primers， 2020， 6（1）： 38-90. doi:10.1038/s41572-020-0160-6 doi: 10.1038/s41572-020-0160-6
5	SOULARUE E， LEPAGE P， COLOMBEL J F， et al. Enterocolitis due to immune checkpoint inhibitors： a systematic review ［J］. Gut， 2018， 67（11）： 2056-2067. doi:10.1136/gutjnl-2018-316948 doi: 10.1136/gutjnl-2018-316948
6	WEBER J S， KÄHLER K C， HAUSCHILD A. Management of immune-related adverse events and kinetics of response with ipilimumab ［J］. J Clin Oncol， 2012， 30（21）： 2691-2697. doi:10.1200/jco.2012.41.6750 doi: 10.1200/jco.2012.41.6750
7	ASCIERTO P A， DEL VECCHIO M， ROBERT C， et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma： a randomised， double-blind， multicentre， phase 3 trial ［J］. Lancet Oncol， 2017， 18（5）： 611-622. doi:10.1016/s1470-2045(17)30231-0 doi: 10.1016/s1470-2045(17)30231-0
8	PAGAN A， ARROYO-MARTINEZ Y M， TANDON A， et al. Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis ［J］. Cureus， 2020， 12（6）： e8613-e8617.
9	KELLY-GOSS M R， BADRAN Y R， DOUGAN M. Update on Immune Checkpoint Inhibitor Enterocolitis ［J］. Curr Gastroenterol Rep， 2022， 24（12）： 171-181. doi:10.1007/s11894-022-00852-7 doi: 10.1007/s11894-022-00852-7
10	ABU-SBEIH H， FALECK D M， RICCIUTI B， et al. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease ［J］. J Clin Oncol， 2020， 38（6）： 576-583. doi:10.1200/jco.19.01674 doi: 10.1200/jco.19.01674
11	WEINGARDEN A R， GUBATAN J， SINGH S， et al. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival ［J］. World J Gastroenterol， 2022， 28（39）： 5750-5763. doi:10.3748/wjg.v28.i39.5750 doi: 10.3748/wjg.v28.i39.5750
12	ROUTY B， GOPALAKRISHNAN V， DAILLÈRE R， et al. The gut microbiota influences anticancer immunosurveillance and general health ［J］. Nat Rev Clin Oncol， 2018， 15（6）： 382- 396. doi:10.1038/s41571-018-0006-2 doi: 10.1038/s41571-018-0006-2
13	ABU-SBEIH H， HERRERA L N， TANG T， et al. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis ［J］. J Immunother Cancer， 2019， 7（1）： 242-253. doi:10.1186/s40425-019-0714-x doi: 10.1186/s40425-019-0714-x
14	HASAN ALI O， BERNER F， BOMZE D， et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors ［J］. Eur J Cancer， 2019， 107： 8-14. doi:10.1016/j.ejca.2018.11.009 doi: 10.1016/j.ejca.2018.11.009
15	WÖLFFER M， BATTKE F， SCHULZE M， et al. Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma ［J］. Cancers（Basel）， 2022， 14（2）： 302-323. doi:10.3390/cancers14020302 doi: 10.3390/cancers14020302
16	OKIYAMA N， TANAKA R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors ［J］. Allergol Int， 2022， 71（2）： 169-178. doi:10.1016/j.alit.2022.01.001 doi: 10.1016/j.alit.2022.01.001
17	ZHOU X， CHEN X， HAN L， et al. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy ［J］. Clin Sci， 2022， 136（10）： 771-785. doi:10.1042/cs20210042 doi: 10.1042/cs20210042
18	MILLING L， ZHANG Y， IRVINE D J. Delivering safer immunotherapies for cancer ［J］. Adv Drug Deliv Rev， 2017， 114： 79-101. doi:10.1016/j.addr.2017.05.011 doi: 10.1016/j.addr.2017.05.011
19	YANG H， YAO Z， ZHOU X， et al. Immune-related adverse events of checkpoint inhibitors： Insights into immunological dysregulation ［J］. Clin Immunol， 2020， 213： 108377-108387. doi:10.1016/j.clim.2020.108377 doi: 10.1016/j.clim.2020.108377
20	KUMAR P， SAINI S， PRABHAKAR B S. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis ［J］. Semin Cancer Biol， 2020， 64： 29-35. doi:10.1016/j.semcancer.2019.01.006 doi: 10.1016/j.semcancer.2019.01.006
21	KUMAR P， BHATTACHARYA P， PRABHAKAR B S. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity ［J］. J Autoimmun， 2018， 95： 77-99. doi:10.1016/j.jaut.2018.08.007 doi: 10.1016/j.jaut.2018.08.007
22	LUOMA A M， SUO S， WILLIAMS H L， et al. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy ［J］. Cell， 2020， 182（3）： 655-671. doi:10.1016/j.cell.2020.06.001 doi: 10.1016/j.cell.2020.06.001
23	BLASCHITZ C， RAFFATELLU M. Th17 cytokines and the gut mucosal barrier ［J］. J Clin Immunol， 2010， 30（2）： 196-203. doi:10.1007/s10875-010-9368-7 doi: 10.1007/s10875-010-9368-7
24	WESTDORP H， SWEEP M W D， GORRIS M A J， et al. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis ［J］. Front Immunol， 2021， 12： 768957. doi:10.3389/fimmu.2021.768957 doi: 10.3389/fimmu.2021.768957
25	AL-QADAMI G， VAN SEBILLE Y， LE H， et al. Gut microbiota： implications for radiotherapy response and radiotherapy-induced mucositis ［J］. Expert Rev Gastroenterol Hepatol， 2019， 13（5）： 485-496. doi:10.1080/17474124.2019.1595586 doi: 10.1080/17474124.2019.1595586
26	SUN S， LUO L， LIANG W， et al. Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade ［J］. Pro Nat Acad Sci U S A， 2020， 117（44）： 27509-27515. doi:10.1073/pnas.1921223117 doi: 10.1073/pnas.1921223117
27	CHAPUT N， LEPAGE P， COUTZAC C， et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab ［J］. Ann Oncol， 2017， 28（6）： 1368-1379. doi:10.1093/annonc/mdx108 doi: 10.1093/annonc/mdx108
28	TAO R， DE ZOETEN E F， OZKAYNAK E， et al. Deacetylase inhibition promotes the generation and function of regulatory T cells ［J］. Nat Med， 2007， 13（11）： 1299-1307. doi:10.1038/nm1652 doi: 10.1038/nm1652
29	RENGA G， NUNZI E， PARIANO M， et al. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite ［J］. J Immunother Cancer， 2022， 10（3）： e003725. doi:10.1136/jitc-2021-003725 doi: 10.1136/jitc-2021-003725
30	FRIEDMAN C F， PROVERBS-SINGH T A， POSTOW M A. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors： A Review ［J］. JAMA Oncol， 2016， 2（10）： 1346-1353. doi:10.1001/jamaoncol.2016.1051 doi: 10.1001/jamaoncol.2016.1051
31	DEPUTY M， DEVANABOINA R， BAKIR I AL， et al. The role of faecal calprotectin in the diagnosis of inflammatory bowel disease ［J］. BMJ， 2023， 380： e068947. doi:10.1136/bmj-2021-068947 doi: 10.1136/bmj-2021-068947
32	ZOU F， WANG X， GLITZA OLIVA I C， et al. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis ［J］. J Immunother Cancer， 2021， 9（1）： e002058. doi:10.1136/jitc-2020-002058 doi: 10.1136/jitc-2020-002058
33	NISHIDA T， IIJIMA H， ADACHI S. Immune checkpoint inhibitor-induced diarrhea/colitis： Endoscopic and pathologic findings ［J］. World J Gastrointest Pathophysiol， 2019， 10（2）： 17-28. doi:10.4291/wjgp.v10.i2.17 doi: 10.4291/wjgp.v10.i2.17
34	WANG Y， ABU-SBEIH H， MAO E， et al. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis ［J］. Inflamm Bowel Dis， 2018， 24（8）： 1695-1705. doi:10.1093/ibd/izy104 doi: 10.1093/ibd/izy104
35	DOUGAN M， WANG Y， RUBIO-TAPIA A， et al. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis： Expert Review ［J］. Gastroenterology， 2021， 160（4）： 1384-1393. doi:10.1053/j.gastro.2020.08.063 doi: 10.1053/j.gastro.2020.08.063
36	HUGHES M S， MOLINA G E， CHEN S T， et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors ［J］. J Immunother Cancer， 2019， 7（1）： 292-302. doi:10.1186/s40425-019-0756-0 doi: 10.1186/s40425-019-0756-0
37	GARCIA-NEUER M， MARMARELIS M E， JANGI S R， et al. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients ［J］. Cancer Immunol Res， 2017， 5（4）： 286-291. doi:10.1158/2326-6066.cir-16-0302 doi: 10.1158/2326-6066.cir-16-0302
38	Common terminology criteria for adverse events （Ctcae V 5.0）［EB/OL］.
39	BADRAN Y R， SHIH A， LEET D， et al. Immune checkpoint inhibitor-associated celiac disease ［J］. J Immunother Cancer， 2020， 8（1）： e00958. doi:10.1136/jitc-2020-000958 doi: 10.1136/jitc-2020-000958
40	SINGH B P， MARSHALL J L， HE A R. Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors ［J］. Oncologist， 2020， 25（3）： 197-202. doi:10.1634/theoncologist.2018-0304 doi: 10.1634/theoncologist.2018-0304
41	KIPARIZOSKA S， MURPHY M E， MATTAR M C. Check this out： treatment paradigms in immune-checkpoint inhibitor colitis ［J］. Curr Opin Gastroenterol， 2023， 39（1）： 43-49. doi:10.1097/mog.0000000000000892 doi: 10.1097/mog.0000000000000892
42	NICOLAIDES S， BOUSSIOUTAS A. Immune-Related Adverse Events of the Gastrointestinal System ［J］. Cancers（Basel）， 2023， 15（3）： 691-703. doi:10.3390/cancers15030691 doi: 10.3390/cancers15030691
43	BADRAN Y R， COHEN J V， BRASTIANOS P K， et al. Concurrent therapy with immune checkpoint inhibitors and TNF-α blockade in patients with gastrointestinal immune-related adverse events ［J］. J Immunother Cancer， 2019， 7（1）： 226-237. doi:10.1186/s40425-019-0711-0 doi: 10.1186/s40425-019-0711-0
44	ZOU F， FALECK D， THOMAS A， et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer： a two-center observational study ［J］. J Immunother Cancer， 2021， 9（11）： e003277. doi:10.1136/jitc-2021-003277 doi: 10.1136/jitc-2021-003277
45	DORA D， BOKHARI S M Z， ALOSS K， et al. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events： Emergence of Novel Biomarkers for Cancer Immunotherapy ［J］. Int J Mol Sci， 2023， 24（3）： 2769-2795. doi:10.3390/ijms24032769 doi: 10.3390/ijms24032769
46	MU A， MCDONALD D， JARMUSCH A K， et al. Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection ［J］. Microbiome， 2021， 9（1）： 92-100. doi:10.1186/s40168-021-01026-9 doi: 10.1186/s40168-021-01026-9

分级	腹泻	结肠炎
1级	轻微，相比基线每天< 4次排便或轻微高于基线的造瘘口排便	无症状，仅为临床或诊断所见
2级	中度，每天4～6次排便，或者造瘘口排便中度增加，借助于工具的日常生活活动受限	腹痛，黏液便或血便
3级	重度，每天≥ 7次排便，需要住院治疗，与基线相比造瘘口排便重度增加，自理性日常生活活动受限	剧烈腹痛，腹膜刺激征阳性
4级	危及生命，需要紧急干预	危及生命，需要紧急干预
5级	死亡	死亡

[1]	Yin HUA,Xiaoyan WANG,Zhen WANG,Yongning XIN,Shousheng. LIU. The relationship between ulcerative colitis and the risk of hypothyroidism： A two⁃mendelian randomization study [J]. The Journal of Practical Medicine, 2024, 40(6): 827-832.
[2]	Yujun YI,Xiaoming ZHAI,Huiling LIU,Jin. TAO. The role of PTTG1 in colonic inflammation by regulating intestinal epithelial cells pyroptosis [J]. The Journal of Practical Medicine, 2024, 40(5): 632-638.
[3]	Yuqiao ZHANG,Weijian MEI. Landmark Achievements in Treating Solid Tumors with Immune Checkpoint Inhibitors [J]. The Journal of Practical Medicine, 2024, 40(2): 272-277.
[4]	Xiuli SHI,Jiaqi CHEN,Fan ZHU,Juan ZENG,Na. WU. The effect of miR⁃143⁃3p on pyroptosis of ulcerative colitis cells by regulating TLR2/NF⁃κB/NLRP3 [J]. The Journal of Practical Medicine, 2024, 40(15): 2056-2062.
[5]	Xue PANG,Jianzhuang. GUO. Single-cell transcriptomic bioinformatics study of the pathogenesis of ulcerative colitis [J]. The Journal of Practical Medicine, 2024, 40(15): 2075-2083.
[6]	Shengfang YUAN,Bu WANG,Baoli XIANG,Jianqing ZHAO,Jingjing SHEN,Zhihua. ZHANG. Prediction of immune therapy efficacy and prognosis for advanced non-small cell lung cancer using peripheral blood circulation tumor DNA [J]. The Journal of Practical Medicine, 2024, 40(15): 2110-2115.
[7]	YU Lan, YAN Zhi⁃ hui, LUO Zhe, ZHENG Yan, CUI Lihong. . Effect of Rifaximin combined with Bacillus subtilis on intestinal bacterial overgrowth [J]. The Journal of Practical Medicine, 2023, 39(14): 1815-1819.
[8]	XU Lu, HUANG Liyou, WANG Yanhua, WEN Linchun.. Efficacy and safety ofPD ⁃ 1 inhibitor combined with brain radiotherapy for brain metastases in patients with pan⁃negative non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2022, 38(24): 3100-3105.
[9]	LI Siling, SHANG Kai, HUANG Hongxiang, CHEN Li.. Research progress of radiotherapy combined with immunotherapy in non ⁃ small cell lung cancer [J]. The Journal of Practical Medicine, 2022, 38(23): 3017-3022.
[10]	DONG Jiayi, CHEN Size, SHAO Lijuan, SONG Minghan.. Research progress of CAR⁃T combined immunomodulator in the treatment of solid tumors [J]. The Journal of Practical Medicine, 2022, 38(21): 2643-2648.
[11]	ZHANG Yiting, QIAN Xiang, REN Zhen, DING Hongmei.. Clinical value of fecal calprotectin combined with blood indicators in diagnosis and evaluation of activity of ulcerative colitis [J]. The Journal of Practical Medicine, 2021, 37(9): 1199-1202.
[12]	MENG Fan, CHEN Jun, LIU Yuxia, XIE Lu, LI Zijun, LIU Zhiping.. Dock2 controls enteric bacterial clearance through regulating T cell activity and antigen⁃specific IgG pro⁃ duction [J]. The Journal of Practical Medicine, 2021, 37(8): 1000-1007.
[13]	LI Dailong, WANG Yuke, PANG Yaqi, XU Xinhua. Progress of clinical research on immune checkpoint inhibitorsin advanced hepatocellular carcinoma [J]. The Journal of Practical Medicine, 2021, 37(6): 821-826.
[14]	YI Chufan, FU Weijin.. Role of immune checkpoint inhibitors in treatment of advanced prostate cancer：A literature review [J]. The Journal of Practical Medicine, 2021, 37(12): 1516-1519.
[15]	YE Qiang, CHEN Xiaoyan. . Endocrine toxicity of immune checkpoint inhibitors and clinical response strategies [J]. The Journal of Practical Medicine, 2021, 37(11): 1382-1386.

Advances in the study of immune checkpoint inhibitors⁃related colitis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 46

Related Articles 15

Recommended Articles

Metrics

Comments